NCT02636062

Brief Summary

This study is a non-randomized prospective cohort study that will define the rate of index atherosclerotic plaque development in adults with a prior coronary artery calcium (CAC) score of 0 given prior CAC zero \> 5 years previous. Ancillary testing of serum, whole blood, and endothelial dysfunction will be performed to investigate any detectable systemic processes that predict CAC development.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2017

Typical duration for all trials

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 10, 2015

Completed
11 days until next milestone

First Posted

Study publicly available on registry

December 21, 2015

Completed
1.5 years until next milestone

Study Start

First participant enrolled

July 1, 2017

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2020

Completed
Last Updated

April 18, 2018

Status Verified

April 1, 2018

Enrollment Period

2.4 years

First QC Date

December 10, 2015

Last Update Submit

April 16, 2018

Conditions

Keywords

Coronary diseaseCoronary artery disease (CAD)Endothelial dysfunctionCoronary artery calcium (CAC)

Outcome Measures

Primary Outcomes (1)

  • Number of patients with CAC > 0

    Incident development of any CAC (CAC \> 0) between initial scan \> 5 years previous and re-scan

    5 years

Secondary Outcomes (3)

  • Major adverse cardiovascular events

    5 years

  • Per vessel incident CAC

    5 years

  • Number of patients on statin therapy with incident CAC > 0 compared with statin naïve patients

    5 years

Study Arms (2)

Follow-up CAC > 0

All patients with CAC scores of zero \> 5 years previous will be invited to enroll and undergo repeat CAC scanning. This group will include all patients that develop incident CAC.

Follow-up CAC zero

All patients with CAC scores of zero \> 5 years previous will be invited to enroll and undergo repeat CAC scanning. This group will include all patients who continue to have a CAC of zero.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients (\> 18 years old) with a prior CAC score of 0 \> 5 years ago or more will be contacted to enroll and undergo repeat CAC scanning.

You may qualify if:

  • Adults aged 18 years or older
  • Coronary Artery Calcium scoring test graded as 0 Agatston units

You may not qualify if:

  • Interval development of symptomatic coronary artery disease (defined as prior PCI, CABG, or myocardial infarction) in the time between initial CAC scan and current data review. (These patients will not be enrolled in the trial to undergo repeat CAC testing, but any major cardiovascular events (MACE) will be documented in order to report the 5 year MACE rates amongst CAC zero patients in our population.)
  • Pregnant females
  • Implantable cardiac pacemaker or defibrillator
  • Prior cardiac surgery for valvular heart disease
  • Patients with CAC scores ≥ 1
  • Patients in atrial fibrillation at the time of CAC acquisition

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

The biological specimens collected in this study will be used for future testing and evaluation of exploratory systemic biomarkers with respect to prediction of coronary artery disease (CAD) progression and incident development of CAD. Specifically, samples are being collected to investigate pro-fibrotic and pro-inflammatory makers and the effect on CAD development and progression as measured by coronary artery calcification (CAC). DNA samples will be tested for genetic factors and identify trends amongst patients with CAC development, particularly focusing on those with aggressive, multivessel CAC development.

MeSH Terms

Conditions

Coronary Artery DiseaseAtherosclerosisCoronary Disease

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

  • Dustin M Thomas, MD

    San Antonio Military Medical Center

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
FED
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, Cardiac CT Imaging and Cardiovascular Research

Study Record Dates

First Submitted

December 10, 2015

First Posted

December 21, 2015

Study Start

July 1, 2017

Primary Completion

December 1, 2019

Study Completion

July 1, 2020

Last Updated

April 18, 2018

Record last verified: 2018-04

Data Sharing

IPD Sharing
Will not share